Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on DINKELACKER AG. We currently have 0 research reports from 0 professional analysts.
Frequency of research reports
Research reports on
Eyeing Up Opportunity
24 Mar 17
Produce Investment’s (PIL LN, BUY, T/P 210p) interim profits were well beneath inferred market expectations as delays in the recovery of ex-farm potato prices coincided with unusual costs associated with the company’s implementation of a new ERP system. Interim EBIT fell to £0.2m from £3.4m last year.
N+1 Singer - Morning Song 28-03-2017
28 Mar 17
A G Barr (BAG LN) Share buybacks the main news around FY17 finals | Churchill China (CHH LN) An excellent set of 2016 results and more upgrades | Ergomed (ERGO LN) FY results show strong Services growth; Phase III Zoptrex® data ahead | Instem (INS LN) Investment to accelerate growth trajectory | Severfield (SFR LN) Strong H2 drives upgrades; CEO temporarily steps down due to ill health | Summit Therapeutics (SUMM LN) Strengthening the data package: planned extension of PhaseOut DMD | T. Clarke (CTO LN) Strong conclusion to FY16, record order book
Panmure Morning Note 30-03-2017
30 Mar 17
FY16 PBT of £33.2m has come in towards the top end of the £32.2m-£33.5m range for consensus forecasts which had only very recently been modestly nudged up post the FY16 pre-close trading statement on January 12th. However, we believe the stockmarket will particularly welcome the significantly better than expected cash generation driving a robust net cash position of £32.3m (well ahead of our expectations of £22m) and a full year dividend growth of +17.1% to 17.1p (substantially ahead of our forecasted 15.6p). The medium-term outlook remains positive, with HFG expecting further growth aided by continued focus on NPD and range extensions, whilst HFG now has visibility on strong profit growth with the new Portuguese j/v coming through in the short term and the planned Australian factory longer term. In brief, these strong FY16 results demonstrate HFG is in excellent shape operationally, strategically and financially with the firepower to simultaneously fund additional investment options and maintain an ongoing, attractive progressive dividend policy. We maintain our BUY.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Northampton site visit – well heeled scope for growth
29 Mar 17
Greencore’s (GNC LN, BUY, T/P 310p) 28th March 2017 analyst/investor day – its first to Northampton for five years – delivered a number of positive messages. While there was no trading update, it is clear that momentum in UK Food to Go remains strong and that the site – dedicated to M&S – benefits from continuous expansion and improvement. Greencore remains UK market leader in sandwiches with 45% total share and 59% grocery share.